

CITATION REPORT

List of articles citing

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

DOI: 10.1002/ajh.25595

American Journal of Hematology, 2019, 94, 1266-1287.

Source: <https://exaly.com/paper-pdf/72183469/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
286	Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia. 2019 , 14, 493-504		4
285	Epigenetic regulation of steroidogenic enzymes expressed in peripheral blood mononuclear cells from healthy individuals and from patients with chronic lymphocytic leukemia. 2020 , 204, 105767		
284	Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia. 2020 , 13, 9679-9688		9
283	The impact of immune checkpoint inhibitors in patients with chronic lymphocytic leukemia (CLL): A protocol for a systematic review and meta-analysis of randomized controlled trials. 2020 , 99, e21167		1
282	Heterogeneity of Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. <i>Frontiers in Oncology</i> , 2020 , 10, 593383	5.3	13
281	Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia. 2020 , 80, 1973-1980		2
280	Advances of Nanoparticles for Leukemia Treatment. 2020 , 6, 6478-6489		4
279	Macrophage Polarization in Chronic Lymphocytic Leukemia: Nurse-Like Cells Are the Caretakers of Leukemic Cells. 2020 , 8,		1
278	Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. 2021 , 144, 365-379		5
277	COVID-19 and fortuitous discovery of chronic lymphocytic leukemia: biological findings and therapeutic challenges. 2020 , 36, 286		4
276	Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report. <i>Frontiers in Oncology</i> , 2020 , 10, 584607	5.3	
275	Targeting Casein Kinase 1 (CK1) in Hematological Cancers. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	14
274	Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. 2020 , 2020, 357-362		6
273	HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the EBTCL1 Model. 2020 , 11, 590072		2
272	Meta-Analysis Reveals Significant Sex Differences in Chronic Lymphocytic Leukemia Progression in the Transgenic Mouse Model. <i>Cancers</i> , 2020 , 12,	6.6	1
271	Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients. 2020 , 10, 18427		4
270	An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. 2020 , 13, 1039-1046		1

269	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. 2020 , 9, 8468-8479		8
268	LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. 2020 , 99, 2343-2349		2
267	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. 2020 , 21, 1188-1200		92
266	Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. 2020 , 8, 40		10
265	Role of Chronic Lymphocytic Leukemia (CLL)-Derived Exosomes in Tumor Progression and Survival. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	11
264	Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020 , 12,	6.6	0
263	Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. <i>Cancers</i> , 2020 , 12,	6.6	3
262	Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. 2020 , 11, 594556		18
261	Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia. 2020 , 9, IJH31		2
260	Aniline-containing derivatives of parthenolide: Synthesis and anti-chronic lymphocytic leukaemia activity. 2020 , 76, 131631		0
259	Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. 2020 , 60, 130-137		1
258	ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. 2020 , 38, 2849-2861		131
257	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020 , 136, 763-766	2.2	17
256	Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects. 2020 , 13, 4877-4892		8
255	Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. <i>Blood</i> , 2020 , 136, 1946-1955	2.2	14
254	Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. <i>Frontiers in Oncology</i> , 2020 , 10, 848	5.3	2
253	Cell-free IgG-aggregates in plasma of patients with chronic lymphocytic leukemia cause chronic activation of the classical complement pathway. 2020 , 15, e0230033		1
252	An Anecdotal Case Report of Chronic Lymphatic Leukemia with del(11q) Treated with Ibrutinib: Artificial Nourishment and Physical Activity Program. 2020 , 17,		8

251	Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. 2020 , 36, 1481-1495		2
250	B cell signalling pathways-New targets for precision medicine in chronic lymphocytic leukaemia. 2020 , 92, e12931		4
249	Chronic Lymphocytic Leukemia: Real-World Data From India. 2020 , 6, 866-872		7
248	New Palladium(II) and Platinum(II) Complexes Based on Pyrrole Schiff Bases: Synthesis, Characterization, X-ray Structure, and Anticancer Activity. 2020 , 5, 14942-14954		28
247	The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?. 2020 , 13, 771-779		2
246	Nanocarriers as Magic Bullets in the Treatment of Leukemia. 2020 , 10,		20
245	Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib. 2020 , 25, 25-35		10
244	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. <i>Cancers</i> , 2020 , 12,	6.6	13
243	Diagnose und Behandlung der chronischen lymphatischen Leukämie. 2020 , 15, 8-16		
242	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?. 2020 , 111, 642-656		1
241	A drug potency signature links progression of chronic lymphocytic leukemia to mitochondria-related stress responses and metabolic reprogramming under hypoxia. 2020 , 398, 115016		0
240	The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. 2020 , 4, 1407-1418		3
239	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. 2020 , 395, 1278-1291		201
238	Validation of the Chinese EORTC chronic lymphocytic leukaemia module - application of classical test theory and item response theory. 2020 , 18, 96		0
237	Pharmacists' Role in Managing Patients with Chronic Lymphocytic Leukemia. 2020 , 8,		3
236	A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia. 2021 , 51, 408-415		1
235	Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells. 2021 , 192, 333-342		2
234	Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?. 2021 , 193, 723-726		1

233	2-[F]-FDG PET/CT Role in Detecting Richter Transformation of Chronic Lymphocytic Leukemia and Predicting Overall Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e277-e283	2	9
232	Development of molecular intervention strategies for B-cell lymphoma. 2021 , 14, 241-252		
231	Association of MTHFR C677T and A1298C Polymorphisms with Susceptibility to Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. 2021 , 50, 83-92		2
230	Notch in Human Cancers: A Complex Tale. 2021 ,		
229	Der Stand der Therapie bei der refraktären/rezidivierenden chronischen lymphatischen Leukämie: Neuartige Wirkstoffe im Fokus. 2021 , 8, 59-69		
228	Successful treatment of "accelerated" chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases. 2021 , 15, 100247		1
227	The NLRP3 Inflammasome and Its Role in the Pathogenicity of Leukemia. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
226	Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks. 2021 , 11, 322		0
225	Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphomas. 2021 , 195-224		
224	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. 2021 , 106, 493-499		1
223	Tomentosin inhibits cell proliferation and induces apoptosis in MOLT-4 leukemia cancer cells through the inhibition of mTOR/PI3K/Akt signaling pathway. 2021 , 35, e22719		2
222	HSCT in Malignancies. 2021 , 99-114		
221	New Perspectives in Personalization of Therapy for Hematological Cancers.		
220	Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects. 2021 , 15, 99-110		0
219	Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. 2021 , 5, 334-343		9
218	HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia. 2021 , 19, 42		
217	Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib. 2021 , 1		1
216	Beyond DNA-targeting in Cancer Chemotherapy. <i>Emerging Frontiers - A Review</i> . 2021 , 21, 28-47		3

215	EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. 2021 , 26, 242-249		7
214	Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor. <i>Current Oncology</i> , 2021 , 28, 837-841	2.8	6
213	Blood cancer health disparities in the United States Hispanic population. 2021 , 7,		1
212	RGDS-Modified Superporous Poly(2-Hydroxyethyl Methacrylate)-Based Scaffolds as 3D In Vitro Leukemia Model. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
211	A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. 2021 , 39, 1099-1105		2
210	The PI3K Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression. 2021 , 12, 608625		0
209	Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. 2021 , 34, 108845		
208	Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion. <i>Frontiers in Oncology</i> , 2021 , 11, 564383	5.3	2
207	TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	99
206	Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. 2021 , 15, 919-926		4
205	Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. 2021 , 110, 220-228		1
204	The Role of 2-[18F]-FDG PET/CT in Detecting Richter Transformation in Chronic Lymphocytic Leukemia: A Systematic Review. 2021 , 1, 65-76		0
203	Phyllanthin inhibits MOLT-4 leukemic cancer cell growth and induces apoptosis through the inhibition of AKT and JNK signaling pathway. 2021 , 35, 1-10		1
202	Current and future treatment strategies in chronic lymphocytic leukemia. 2021 , 14, 69		2
201	Optimizing Treatment of Chronic Lymphocytic Leukemia. 2021 , 12, 325-328		
200	Renal Diseases Associated with Hematologic Malignancies and Thymoma in the Absence of Renal Monoclonal Immunoglobulin Deposits. 2021 , 11,		0
199	Geriatik Hastalarda Hematolojik Malignitelerin Dağılımı ve Tedavi Yöntemleri. 2021 , 14, 69		
198	Targeting the tumor microenvironment in chronic lymphocytic leukemia. <i>Haematologica</i> , 2021 , 106, 2317-2324	6.3	246

197	Leucémie lymphoïde chronique : de la biologie à la thérapeutique. 2021 , 2021, 32-43		
196	Consumption of Ultra-Processed Food and Drinks and Chronic Lymphocytic Leukemia in the MCC-Spain Study. 2021 , 18,		2
195	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. 2021 , 11,		2
194	Smudge cells percentage on blood smear is a reliable prognostic marker in chronic lymphocytic leukemia. 2021 ,		1
193	The Impact of Chlorambucil and Valproic Acid on Cell Viability, Apoptosis and Expression of , , and Genes in Chronic Lymphocytic Leukemia. <i>Cells</i> , 2021 , 10,	7.9	1
192	Screening and monitoring of the BTK mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. 2021 , 194, 355-364		2
191	Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia. 2021 , 1, 249-262		
190	O-GlcNAcylation in early stages of chronic lymphocytic leukemia: Protocol development for flow cytometry. 2021 , 32, 353-362		
189	Identification of Clinically Relevant Subgroups of Chronic Lymphocytic Leukemia Through Discovery of Abnormal Molecular Pathways. <i>Frontiers in Genetics</i> , 2021 , 12, 627964	4.5	0
188	Anti-proliferation and pro-apoptosis effects of miR-582-5p in chronic lymphocytic leukemia via targeting HNRNPA1 and suppression of NF- κ B. 2021 , 17, 357-365		2
187	Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations. <i>Frontiers in Oncology</i> , 2021 , 11, 703254	5.3	0
186	A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia. 2021 , 10, 4387-4396		2
185	Histopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies. 2021 ,		5
184	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
183	The role of cytogenetic and molecular testing in the diagnostics and prognostication of chronic B-cell lymphocytic leukemia. 2021 , 56, 1-17		
182	Proteomics and Drug Repurposing in CLL towards Precision Medicine. <i>Cancers</i> , 2021 , 13,	6.6	0
181			
180	The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. <i>Blood</i> , 2021 , 138, 2372-2382	2.2	5

179	Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints. 2021 , 27, 320-327		0
178	BCR activated CLL B cells use both CR3 (CD11b/CD18) and CR4 (CD11c/CD18) for adhesion while CR4 has a dominant role in migration towards SDF-1. 2021 , 16, e0254853		
177	Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021 , 11, 698572	5.3	1
176	MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells. 2021 , 22, 2191-2198		0
175	Impact of Berberine on the Expression of Apollon Gene in Chronic Lymphocytic Leukemia. 2021 , 1,		
174	CAR T-Cell Therapy in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
173	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. 2021 , 5, 3066-3075		0
172	The Pattern of Use of PET/CT Scans in the Clinical Management of Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 558-563	2	2
171	Deubiquitinases in hematological malignancies. 2021 , 9, 66		3
170	New kid on the block: C-reactive protein-to-albumin ratio as a new prognostic marker for chronic lymphocytic leukemia: Comment on "C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases". 2021 , 14, 101098		
169	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021 , 11, 684621	5.3	1
168	Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function. <i>EJHaem</i> ,	0.9	1
167	Consistent B Cell Receptor Immunoglobulin Features Between Siblings in Familial Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021 , 11, 740083	5.3	1
166	13q14 Deletion and Its Effect on Prognosis of Chronic Lymphocytic Leukemia. 2021 , 13, e16839		
165	Recurrent Chromosomal Abnormalities in Tissues Involved by Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2021 ,		1
164	Molecular Pathology of Mature Lymphoid Malignancies. 2021 , 14, 529-547		
163	The Tumor Microenvironment-Dependent Transcription Factors AHR and HIF-1 α Are Dispensable for Leukemogenesis in the E μ -TCL1 Mouse Model of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021 , 13,	6.6	1
162	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. <i>Cancers</i> , 2021 , 13,	6.6	9

161	Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies. 2021 , 223, 113623		12
160	Prospective of modified polymeric MgO/ZnO nanocomposite sensor for potentiometric determination of chronic myelogenous leukemia medication. 2021 , 331, 112949		1
159	Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study. 2021 , 111, 106671		1
158	Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. <i>Leukemia</i> , 2021 , 35, 1037-1052	10.7	2
157	An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib. 2021 , 15, 100245		
156	Progressive Multifocal Leukoencephalopathy (PML) After Obinutuzumab Treatment for Chronic Lymphocytic Leukaemia (CLL). 2021 , 189-195		
155	Outcomes of Bone Marrow Transplantation. 2021 , 689-730		
154	TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues.		6
153	Myocardial contractility dysfunction in patients with chronic lymphocytic leukemia receiving chemotherapy and their treatment with enalapril. 2020 , 25, 90-97		2
152	Refractory Chronic Lymphocytic Leukemia with Central Nervous System Involvement: A Case Report with Literature Review. 2020 , 11, 487-502		3
151	Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. <i>Blood</i> , 2021 ,	2.2	3
150	Racial and ethnic differences in all-cause mortality among Hispanics diagnosed with follicular lymphoma and chronic lymphocytic leukemia in the Bronx, NY. 2021 , 1		
149	A series of nanoscaled Pt(0)-phosphorus ylide complexes based on [60]fullerene: Synthesis, characterization, and in vitro biological assessments. e6472		
148	The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. <i>Frontiers in Oncology</i> , 2021 , 11, 723722	5.3	
147	Lyn controls chemotaxis and motility of CLL cells via phosphorylation of ROR1.		
146	Paraneoplastic Pemphigus: An Indication for Treatment in Chronic Lymphocytic Leukemia. 2020 , 12, e8316		1
145	Chronic leukaemias in the community. 2020 , 43, 126-130		
144	Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients. 2021 , 1		

143	A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in EBTCL1 mice through the JNK/STAT4/p66Shc axis. 2021 , 174, 105965		
142	Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study. 2021 ,		
141	HSCT in Malignancies. 2020 , 1-16		
140	Outcomes of Bone Marrow Transplantation. 2020 , 1-43		
139	C3 glomerulopathy associated to B-cell chronic lymphocytic leukemia. 2020 , 42, 103-103		0
138	Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in E μ -TCL1 mice. 2020 , 4, 6106-6116		1
137	Gene Expression Profiling Predicts Sensitivity of Chronic Lymphocytic Leukemia Cells to Dasatinib. 2021 , 5, e514		
136	HIGH-RISK SUBTYPES OF CHRONIC LYMPHOCYTIC LEUKEMIA ARE DETECTABLE AS EARLY AS 16 YEARS PRIOR TO DIAGNOSIS. <i>Blood</i> , 2021 ,	2.2	1
135	Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL). 2021 , 11,		0
134	BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production. <i>Cells</i> , 2021 , 10,	7.9	1
133	Flow Cytometric Analysis of ZAP-70 Protein Expression for B-Cell Chronic Lymphocytic Leukemia Prognostication: Usefulness and Limitations. 2020 , 12, e11691		1
132	Impact of clinical staging and demographic data (age and sex) on response to treatment and survival of chronic lymphocytic leukemia patients in Kurdistan Region of Iraq. 2021 , 10, 102		0
131	Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland. 2021 , 1		2
130	Anti-Telomerase Immune Response Predicts Disease Progression in Chronic Lymphocytic Leukemia. 2021 , 1, 35-35		
129	A novel differential diagnosis algorithm for chronic lymphocytic leukemia using immunophenotyping with flow cytometry.. 2021 ,		1
128	Editorial: Recent 3D Tumor Models for Testing Immune-Mediated Therapies. 2021 , 12, 798493		0
127	Chronic lymphocytic leukaemia/small lymphocytic lymphoma treatment with rituximab and high-dose methylprednisolone, revisited. 2021 , 10, 8768		1
126	Combination of oridonin and TRAIL induces apoptosis in uveal melanoma cells by upregulating DR5.. 2021 , 14, 1834-1842		0

125	Tumor metastasis: Mechanistic insights and therapeutic interventions.. 2021 , 2, 587-617	8
124	Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients. 2021 , 10, 139	
123	The pattern of bone marrow involvement among chronic lymphocytic leukemia patients and its impact on the disease outcome in Kurdistan Region of Iraq. 2021 , 10, 158	
122	Rapid and non-invasive discrimination of acute leukemia bone marrow supernatants by Raman spectroscopy and multivariate statistical analysis.. 2021 , 210, 114560	1
121	Evaluation of a Prognostic Epigenetic Classification System in Chronic Lymphocytic Leukemia Patients.. 2022 , 17, 11772719211067972	
120	Risk Factors of White Blood Cell Progression Among Patients With Chronic Lymphocytic Leukemia at Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia.. 2022 , 21, 11769351211069902	
119	The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3
118	The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019.. 2022 , 21, 4	1
117	Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL?. 2021 , 9, 795833	
116	An Unusual Case of Chronic Lymphocytic Leukaemia Involving the Cervix.. 2022 , 14, e21823	
115	Vaginal melanoma in Denmark from 1980 to 2018: A population-based study based on genetic profile and survival.. 2022 ,	
114	Dynamic Bayesian networks for prediction of health status and treatment effect in patients with chronic lymphocytic leukemia.. 2022 , 12, 1811	0
113	Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.. 2022 , 22, 148	0
112	Preclinical Validation of Tumor-Penetrating and Interfering Peptides against Chronic Lymphocytic Leukemia.. 2022 ,	1
111	Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms.. 2021 , 12, 784691	0
110	Favorable response to cyclophosphamide in a patient with refractory GuillainBarre syndrome associated with chronic lymphocytic leukemia. 2022 , 13, 1	
109	Personalised Prevention: Increasing or Decreasing Over-Medicalisation, Overdiagnosis and Overtreatment?. 2022 , 87-111	
108	Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells.. 2022 , 10, 838871	0

107	Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges.. <i>Frontiers in Oncology</i> , 2022 , 12, 837531	5.3	0
106	BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion.. 2022 , 21, 59		1
105	Targeted Drug Delivery for Chronic Lymphocytic Leukemia.. 2022 , 39, 441		3
104	Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay.. 2022 , 10,		0
103	Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation.. <i>Frontiers in Oncology</i> , 2022 , 12, 835290	5.3	
102	Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation.. 2022 , 13, 832263		1
101	Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study.. <i>Frontiers in Oncology</i> , 2022 , 12, 840616	5.3	2
100	Unusual Illustration of Richter Transformation in Chronic Lymphocytic Leukemia on FDG PET/CT.. 2022 ,		
99	Kronik lenfositik l�emide tedavi yaklařmlar�Ger�k yařm verisi. 50-55		
98	Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report. 2021 , 100, e27545		
97	Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia.. 2021 , 13, 1155-1165		1
96	Optimization of chronic lymphocytic leukemia treatment using game theory. 2021 , 57-63		
95	The TKI Era in Chronic Leukemias.. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
94	Atypical Mycobacterium Abscessus Infection in Stable Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.. 2021 , 13, e20574		
93	Automated classification of cytogenetic abnormalities in hematolymphoid neoplasms. 2021 ,		2
92	The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia.. <i>Frontiers in Oncology</i> , 2021 , 11, 771669	5.3	0
91	Prognostic significance of microRNA 17-92 cluster expression in Egyptian chronic lymphocytic leukemia patients. 2021 , 33, 37		2
90	Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies.. 2021 , 11,		1

- 89 Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors. **2022**, 36 Suppl 1, 41-44
- 88 Outcome of chronic lymphocytic leukemia with deletion 17p. **2020**, 3, 638
- 87 Comprehensive Assessment of the Risk of Progression of Chronic Lymphocytic Leukemia. **2020**, 48-55
- 86 A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.. *Haematologica*, **2022**, 6.6 0
- 85 DataSheet_1.pdf. **2020**,
- 84 DataSheet_1.pdf. **2020**,
- 83 DataSheet_2.pdf. **2020**,
- 82 DataSheet_3.zip. **2020**,
- 81 Image_1.png. **2020**,
- 80 Table_1.xlsx. **2020**,
- 79 Table_2.xlsx. **2020**,
- 78 Table_3.xlsx. **2020**,
- 77 Table_4.xlsx. **2020**,
- 76 Table_5.xlsx. **2020**,
- 75 Diagnostic Applications of Nuclear Medicine: Leukemias. **2022**, 1-39
- 74 C3 glomerulopathy associated to B-cell chronic lymphocytic leukemia. *Nefrologia*, **2022**, 42, 103-105 0.4
- 73 Palladium(II) and platinum(II) complexes with ONN donor pincer ligand: Synthesis, characterization and in vitro cytotoxicity study. *New Journal of Chemistry*, 3.6 1
- 72 Characterization of metabolic alterations of Chronic Lymphocytic Leukemia in the lymph node microenvironment.. *Blood*, **2022**, 2.2 1

71	miRNAs in Lymphocytic Leukaemias-The miRror of Drug Resistance.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	
70	Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemia. <i>EJHaem</i> ,	0.9	
69	Chronic lymphocytic leukemia includes a tumor subset resembling memory B cells that develop early and persist.		
68	Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. <i>Cancer Research Communications</i> , 2022 , 2, 330-341		0
67	CRISPR/Cas9 in Chronic Lymphocytic Leukemia. <i>Encyclopedia</i> , 2022 , 2, 928-936		1
66	Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2022 , 12,	5.3	1
65	The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia.. <i>Leukemia</i> , 2022 ,	10.7	
64	Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.		5
63	Amino acid metabolism: challenges and opportunities for the therapeutic treatment of leukemia and lymphoma.. <i>Immunology and Cell Biology</i> , 2022 ,	5	0
62	Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships. <i>Frontiers in Genetics</i> , 2022 , 13,	4.5	
61	A novel triple-action inhibitor targeting B-cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemia.		1
60	Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status. <i>Advances in Therapy</i> ,	4.1	1
59	Artificial Intelligence Enhances Diagnostic Flow Cytometry Workflow in the Detection of Minimal Residual Disease of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022 , 14, 2537	6.6	1
58	Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis. <i>Current Oncology</i> , 2022 , 29, 4245-4259	2.8	
57	HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia. <i>Pharmaceuticals</i> , 2022 , 15, 734	5.2	0
56	The Landscape of Exosome-Derived Non-Coding RNA in Leukemia. <i>Frontiers in Pharmacology</i> , 13,	5.6	1
55	A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 6712	6.3	
54	Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia. <i>Pharmaceutics</i> , 2022 , 14, 1294	6.4	

53	Zanubrutinib for the Treatment of B-cell Malignancies. <i>Touch Reviews in Oncology & Haematology</i> , 2022 , 18, 44		
52	Bionanomaterials for cancer therapy. 2022 , 443-468		0
51	CLL-Derived Extracellular Vesicles Impair T-Cell Activation and Foster T-Cell Exhaustion via Multiple Immunological Checkpoints. <i>Cells</i> , 2022 , 11, 2176	7.9	1
50	Real-World Persistence and Time to Next Treatment with Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022 ,	2	0
49	A Ferroptosis Molecular Subtype-Related Signature for Predicting Prognosis and Response to Chemotherapy in Patients with Chronic Lymphocytic Leukemia. <i>BioMed Research International</i> , 2022 , 2022, 1-24	3	2
48	Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukemia. <i>Molecular Oncology</i> ,	7.9	1
47	High-Throughput CRISPR Screening in Hematological Neoplasms. <i>Cancers</i> , 2022 , 14, 3612	6.6	0
46	Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.		1
45	Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia.		
44	Bioinformatics Analysis Based on TCGA: MUC16 Mutation Correlates with Clinical Outcome in Gastric Cancer. 2022 , 2022, 1-9		
43	A peek into the world of CLL genomics. 2022 , 5, 46		0
42	Diagnostic Applications of Nuclear Medicine: Leukemias. 2022 , 529-567		0
41	What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment. 2022 , 6, e771		0
40	La leucémie lymphoïde chronique, un intrus souvent discret et un objet de réflexion philosophique. 2022 , 38, 718-721		0
39	Expression of BCL11A in chronic lymphocytic leukaemia.		0
38	Biomarkers for immune checkpoint inhibitors in solid tumors.		0
37	Chronic Lymphocytic Leukemia Involving the Liver Without High-Grade Transformation. 2022 , 1,		0
36	Identifying a novel ferroptosis-related prognostic score for predicting prognosis in chronic lymphocytic leukemia. 13,		2

- 35 Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment. **2022**, 2022, 1-21 ○
- 34 Clinical significance of serum sCD23 and B-cell maturation antigen levels in patients with chronic lymphocytic leukemia. **2022**, 0 ○
- 33 IFN- γ enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway. 1-8 ○
- 32 Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia. 1-13 ○
- 31 Competing endogenous RNA networks related to prognosis in chronic lymphocytic leukemia: comprehensive analyses and construction of a novel risk score model. **2022**, 10, ○
- 30 Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax. **2022**, 13, ○
- 29 Fibrillary and immunotactoid glomerulopathies in the Hunter region: a retrospective cohort study. ○
- 28 The role of NPM1 alternative splicing in patients with chronic lymphocytic leukemia. **2022**, 17, e0276674 ○
- 27 Ezrin is highly expressed and a druggable target in chronic lymphocytic leukemia. **2022**, 121146 ○
- 26 Diagnostic and Therapeutic Implications of Long Non-Coding RNAs in Leukemia. **2022**, 12, 1770 ○
- 25 How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?. ○
- 24 Bendamustine-Rituximab in Young CLL: Relevance in the Era of Small Molecule Inhibitors. ○
- 23 Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia. **2022**, 23, 14249 1
- 22 ASSOCIATION OF THE FREQUENCY OF SF3B1 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH THE STRUCTURE OF THE B-CELL RECEPTOR. **2022**, 427-434 ○
- 21 Identification of Six Diagnostic Biomarkers for Chronic Lymphocytic Leukemia Based on Machine Learning Algorithms. **2022**, 2022, 1-19 ○
- 20 INTEGRATED BIOINFORMATIC ANALYSIS TO EVALUATE TARGET GENES AND PATHWAYS IN CHRONIC LYMPHOCYTIC LEUKEMIA. **2023**, 47, 22-22 ○
- 19 Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy. **2023**, 15, 132 ○
- 18 A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States. ○

- 17 New palladium (II) complexes from halogen substituted Schiff base ligands: Synthesis, spectroscopic, biological activity, density functional theory, and molecular docking investigations. **2023**, 552, 121505 ○
- 16 Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using A Semi-Markovian Model Approach in R. **2023**, 36, 10-17 ○
- 15 miRNAs as cornerstones in chronic lymphocytic leukemia pathogenesis and therapeutic resistance□ An emphasis on the interaction of signaling pathways. **2023**, 243, 154363 ○
- 14 Characterization of clonal immunoglobulin heavy V-D-J gene rearrangements in Chinese patients with chronic lymphocytic leukemia: Clinical features and molecular profiles. 13, ○
- 13 Secondary involvement of gallbladder by acute lymphoblastic leukemia presenting clinically as cholecystitis in a young patient: a case report. **2023**, 21, ○
- 12 Perspectives on the Application of Cytogenomic Approaches in Chronic Lymphocytic Leukaemia. **2023**, 13, 964 ○
- 11 Emerging Therapies in CLL in the Era of Precision Medicine. **2023**, 15, 1583 ○
- 10 Phase I Clinical Trial. Safety of Baricitinib to prevent respiratory insufficiency in oncohematological patients affected by Coronavirus Disease-19: BARCOVID19 study. ○
- 9 Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia. ○
- 8 Venetoclax in Relapse/Refractory AL Amyloidosis□ Multicenter International Retrospective Real-World Study. **2023**, 15, 1710 ○
- 7 Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis. **2023**, 15, 1996 ○
- 6 Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL). 1-8 ○
- 5 The role of Bruton□ kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib. **2023**, ○
- 4 Extracellular Vesicles in Chronic Lymphocytic Leukemia: Tumor Microenvironment Messengers as a Basis for New Targeted Therapies?. **2023**, 15, 2307 ○
- 3 The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia. ○
- 2 An Extremely Rare Case of Prostate and Bladder Wall Involvement of Chronic Lymphocytic Leukemia. **2023**, 11, 232470962311681 ○
- 1 Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada. 1-10 ○